person · Reporting owner

Adsett Roger

Disclosed activity across 3 companies

Tapewire entity: 24269
SEC CIK: 0001685904

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Definium Therapeutics, Inc.DFTX · Entity 3884	Director	June 11, 2026	June 15, 2026
INSMED IncINSM · Entity 3174	Chief Operating Officer	August 10, 2026	August 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Definium Therapeutics, Inc.

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	3,555	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Grant · Acquired 3,555 · Balance 3,555 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-10	Direct	14,620	Reported balance After 2026-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-11 · Grant · Acquired 14,620 · Balance 14,620 F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.

F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

INSMED Inc

Report date August 10, 2026 · Filed August 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	181,024	Reported balance After 2026-08-10 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-08-10 · Exercise / conversion · Acquired 82,280 · Balance 181,024 F1: Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
Common StockSEC Table I · non-derivative	Direct	257,624	Reported balance After 2026-08-10 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-08-10 · Exercise / conversion · Acquired 76,600 · Balance 257,624
Common StockSEC Table I · non-derivative	Direct	338,594	Reported balance After 2026-08-10 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2026-08-10 · Exercise / conversion · Acquired 80,970 · Balance 338,594
Common StockSEC Table I · non-derivative	Direct	98,744	Reported balance After 2026-08-10 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2026-08-10 · Sale · Disposed 239,850 · Balance 98,744 F2: This is the weighted average sales price representing 239,850 shares sold at prices ranging from $133.00 to $133.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.67 · Expires 2027-01-05	Direct	0	Reported balance After 2026-08-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-08-10 · Exercise / conversion · Disposed 82,280 · Balance 0 F3: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2027-05-17	Direct	0	Reported balance After 2026-08-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-08-10 · Exercise / conversion · Disposed 76,600 · Balance 0 F3: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.46 · Expires 2028-01-04	Direct	0	Reported balance After 2026-08-10 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-08-10 · Exercise / conversion · Disposed 80,970 · Balance 0 F3: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan.

F2: This is the weighted average sales price representing 239,850 shares sold at prices ranging from $133.00 to $133.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F3: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Landos Biopharma, Inc.

Report date May 23, 2024 · Filed May 23, 2024

Section 16 reporting ended · disclosed 2024-05-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30	Direct	Reported balance After 2024-05-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-05-23 · Disposition to issuer · Disposed 1,800 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10	Direct	Reported balance After 2024-05-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-05-23 · Disposition to issuer · Disposed 1,800 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70	Direct	Reported balance After 2024-05-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-23 · Disposition to issuer · Disposed 3,600 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 10, 2026 Filed Aug 12, 2026 21:04 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	80,970	$0.00 Strike: $30.46	$0.00	Disclosure SEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · derivative · entry 7 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,970 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
August 10, 2026 Filed Aug 12, 2026 21:04 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	76,600	$0.00 Strike: $17.16	$0.00	Disclosure SEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · derivative · entry 6 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,600 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
August 10, 2026 Filed Aug 12, 2026 21:04 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	82,280	$0.00 Strike: $13.67	$0.00	Disclosure SEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · derivative · entry 5 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,280 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
August 10, 2026 Filed Aug 12, 2026 21:04 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	239,850	$133.27	$31,964,809.50	Disclosure SEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · nonDerivative · entry 4 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,744 F2 · price: This is the weighted average sales price representing 239,850 shares sold at prices ranging from $133.00 to $133.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
August 10, 2026 Filed Aug 12, 2026 21:04 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	80,970	$30.46	$2,466,346.20	Disclosure SEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · nonDerivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 10, 2026 Filed Aug 12, 2026 21:04 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	76,600	$17.16	$1,314,456.00	Disclosure SEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 10, 2026 Filed Aug 12, 2026 21:04 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	82,280	$13.67	$1,124,767.60	Disclosure SEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:30 UTC	Definium Therapeutics, Inc. DFTX · Entity 3884	GrantStock Option (Right to Buy) · Derivative	14,620	$0.00 Strike: $24.11	$0.00	Disclosure SEC source: 0001193125-26-271155 · ownership.xml · derivative · entry 2 Adsett Roger · CIK 0001685904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,620 Underlying: Common Shares · 14,620 shares Expires 2036-06-10 F2 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:30 UTC	Definium Therapeutics, Inc. DFTX · Entity 3884	GrantCommon Shares	3,555	$0.00	$0.00	Disclosure SEC source: 0001193125-26-271155 · ownership.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,555 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 03, 2026 Filed Jun 5, 2026 20:15 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	2,370	$102.27	$242,379.90	Disclosure SEC source: 0001685904-26-000012 · wk-form4_1780690556.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,603 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document
May 13, 2026 Filed May 15, 2026 20:07 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	5,837	$116.18	$678,142.66	Disclosure SEC source: 0001685904-26-000010 · wk-form4_1778875668.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,973 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document
April 01, 2026 Filed Apr 3, 2026 20:07 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	88,060	$0.00 Strike: $14.56	$0.00	Disclosure SEC source: 0001685904-26-000008 · wk-form4_1775246852.xml · derivative · entry 5 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,060 shares Expires 2026-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
April 01, 2026 Filed Apr 3, 2026 20:07 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	62,344	$164.95	$10,283,642.80	Disclosure SEC source: 0001685904-26-000008 · wk-form4_1775246852.xml · nonDerivative · entry 4 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,810 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 62,344 shares sold at prices ranging from $164.52 to $165.45 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
April 01, 2026 Filed Apr 3, 2026 20:07 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	19,001	$164.11	$3,118,254.11	Disclosure SEC source: 0001685904-26-000008 · wk-form4_1775246852.xml · nonDerivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,154 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 19,001 shares sold at prices ranging from $163.52 to $164.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
April 01, 2026 Filed Apr 3, 2026 20:07 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	6,715	$163.18	$1,095,753.70	Disclosure SEC source: 0001685904-26-000008 · wk-form4_1775246852.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,155 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 6,715 shares sold at prices ranging from $162.52 to $163.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
April 01, 2026 Filed Apr 3, 2026 20:07 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	88,060	$14.56	$1,282,153.60	Disclosure SEC source: 0001685904-26-000008 · wk-form4_1775246852.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
February 03, 2026 Filed Feb 4, 2026 21:20 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	791	$156.17	$123,530.47	Disclosure SEC source: 0001685904-26-000006 · wk-form4_1770240004.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,810 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document
January 29, 2026 Filed Jan 30, 2026 01:35 UTC	Definium Therapeutics, Inc. DFTX · Entity 3884	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $17.24	$0.00	Disclosure SEC source: 0001193125-26-029915 · ownership.xml · derivative · entry 1 Adsett Roger · CIK 0001685904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2036-01-28 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable over a three-year period with 1/3 vesting on the first anniversary of the date of the grant and the remaining vesting in 24 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document
January 08, 2026 Filed Jan 8, 2026 22:22 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	2,059	$174.17	$358,616.03	Disclosure SEC source: 0001685904-26-000004 · wk-form4_1767910926.xml · nonDerivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,601 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:22 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	802	$175.07	$140,406.14	Disclosure SEC source: 0001685904-26-000004 · wk-form4_1767910926.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,660 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document
January 06, 2026 Filed Jan 8, 2026 22:22 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	1,429	$173.33	$247,688.57	Disclosure SEC source: 0001685904-26-000004 · wk-form4_1767910926.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,462 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:05 UTC	INSMED Inc INSM · Entity 3174	GrantStock Option (right to buy) · Derivative	31,280	$0.00 Strike: $177.12	$0.00	Disclosure SEC source: 0001685904-26-000002 · wk-form4_1767733553.xml · derivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,280 Underlying: Common Stock · 31,280 shares Expires 2036-01-02 F4 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:05 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	5,998	Not disclosed	Not disclosed	Disclosure SEC source: 0001685904-26-000002 · wk-form4_1767733553.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,891 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F2 · price: Each RSU was granted on January 2, 2026 for no consideration. F3 · balance_after: Includes 256 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document
August 19, 2025 Filed Aug 21, 2025 21:05 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	4,807	$128.27	$616,593.89	Disclosure SEC source: 0001685904-25-000004 · wk-form4_1755810352.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,637 F2 · price: This is the weighted average sales price representing 4,807 shares sold at prices ranging from $128.00 to $128.72 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
August 19, 2025 Filed Aug 21, 2025 21:05 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	20,193	$127.42	$2,572,992.06	Disclosure SEC source: 0001685904-25-000004 · wk-form4_1755810352.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,444 F1 · price: This is the weighted average sales price representing 20,193 shares sold at prices ranging from $127.00 to $127.99 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
June 16, 2025 Filed Jun 18, 2025 20:15 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	4,186	$99.32	$415,753.52	Disclosure SEC source: 0001628280-25-032112 · wk-form4_1750277724.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,637 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 4,186 shares sold at prices ranging from $98.94 to $99.83 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
June 16, 2025 Filed Jun 18, 2025 20:15 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	6,500	$98.50	$640,250.00	Disclosure SEC source: 0001628280-25-032112 · wk-form4_1750277724.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,823 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 6,500 shares sold at prices ranging from $97.93 to $98.92 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
June 03, 2025 Filed Jun 4, 2025 21:36 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	1,860	$71.50	$132,990.00	Disclosure SEC source: 0001628280-25-029406 · wk-form4_1749073009.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,323 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document
May 15, 2025 Filed May 19, 2025 21:06 UTC	INSMED Inc INSM · Entity 3174	GrantStock Option (right to buy) · Derivative	31,610	$0.00 Strike: $67.22	$0.00	Disclosure SEC source: 0001628280-25-026585 · wk-form4_1747688771.xml · derivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,610 Underlying: Common Stock · 31,610 shares Expires 2035-05-15 F3 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. Read SEC document
May 15, 2025 Filed May 19, 2025 21:06 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	6,508	$0.00	$0.00	Disclosure SEC source: 0001628280-25-026585 · wk-form4_1747688771.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,183 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F2 · price: Each RSU was granted on May 15, 2025 for no consideration. Read SEC document
May 14, 2025 Filed May 15, 2025 20:26 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	1,925	$65.61	$126,299.25	Disclosure SEC source: 0001628280-25-025972 · wk-form4_1747340793.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,675 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document
May 13, 2025 Filed May 15, 2025 20:26 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	7,482	$67.81	$507,354.42	Disclosure SEC source: 0001628280-25-025972 · wk-form4_1747340793.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,600 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:45 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	26,141	$79.33	$2,073,765.53	Disclosure SEC source: 0001628280-25-005166 · wk-form4_1739396737.xml · nonDerivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,082 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 26,141 shares sold at prices ranging from $78.61 to $79.54 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:45 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	5,781	$78.36	$452,999.16	Disclosure SEC source: 0001628280-25-005166 · wk-form4_1739396737.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,223 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 5,781 shares sold at prices ranging from $78.10 to $78.59 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
February 10, 2025 Filed Feb 12, 2025 21:45 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	11,053	$77.02	$851,302.06	Disclosure SEC source: 0001628280-25-005166 · wk-form4_1739396737.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,004 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 11,053 shares sold at prices ranging from $76.74 to $77.60 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
February 07, 2025 Filed Feb 7, 2025 22:11 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	100	$79.57	$7,957.00	Disclosure SEC source: 0001628280-25-004463 · wk-form4_1738966283.xml · nonDerivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,057 F2 · shares: Shares sold to satisfy tax withholding obligations upon the vesting of PSUs and to cover related broker fees. F4 · price: This is the weighted average sales price representing 100 shares sold at prices ranging from $79.56 to $79.57 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
February 06, 2025 Filed Feb 7, 2025 22:11 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	45,605	$80.90	$3,689,444.50	Disclosure SEC source: 0001628280-25-004463 · wk-form4_1738966283.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,157 F2 · shares: Shares sold to satisfy tax withholding obligations upon the vesting of PSUs and to cover related broker fees. F3 · price: This is the weighted average sales price representing 45,605 shares sold at prices ranging from $80.57 to $81.43 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document
February 05, 2025 Filed Feb 7, 2025 22:11 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	88,680	$0.00	$0.00	Disclosure SEC source: 0001628280-25-004463 · wk-form4_1738966283.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,762 F1 · shares: Represents shares of common stock acquired upon vesting of Performance Stock Units (PSUs) that were originally granted on January 6, 2022, which vested on February 5, 2025 upon the achievement of the applicable performance and service conditions. Read SEC document
January 14, 2025 Filed Jan 16, 2025 21:37 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	1,457	$68.72	$100,125.04	Disclosure SEC source: 0001628280-25-001735 · wk-form4_1737063465.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,082 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:44 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	3,604	$63.62	$229,286.48	Disclosure SEC source: 0001628280-25-001201 · wk-form4_1736552668.xml · nonDerivative · entry 5 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,539 F6 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:44 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	1,298	$63.86	$82,890.28	Disclosure SEC source: 0001628280-25-001201 · wk-form4_1736552668.xml · nonDerivative · entry 4 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,143 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees. Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:44 UTC	INSMED Inc INSM · Entity 3174	GrantStock Option (right to buy) · Derivative	31,930	$0.00 Strike: $65.72	$0.00	Disclosure SEC source: 0001628280-25-001201 · wk-form4_1736552668.xml · derivative · entry 6 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,930 Underlying: Common Stock · 31,930 shares Expires 2035-01-08 F7 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:44 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	6,657	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-001201 · wk-form4_1736552668.xml · nonDerivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,441 F4 · shares: Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F5 · price: Each RSU was granted on January 8, 2025 for no consideration. Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:44 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	1,882	$66.10	$124,400.20	Disclosure SEC source: 0001628280-25-001201 · wk-form4_1736552668.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,784 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees. Read SEC document
January 07, 2025 Filed Jan 10, 2025 23:44 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	2,444	$65.95	$161,181.80	Disclosure SEC source: 0001628280-25-001201 · wk-form4_1736552668.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,666 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees. F2 · price: This is the weighted average sales price representing 2,444 shares sold at prices ranging from $65.85 to $66.21 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F3 · balance_after: Includes 835 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document
May 23, 2024 Filed May 23, 2024 21:45 UTC	Landos Biopharma, Inc. LABP · Entity 90644	Disposition to issuerStock Option (right to buy) · Derivative	3,600	Not disclosed Strike: $14.70	Not disclosed	Disclosure SEC source: 0001415889-24-014337 · form4-05232024_050509.xml · derivative · entry 3 Adsett Roger · CIK 0001685904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. Read SEC document
May 23, 2024 Filed May 23, 2024 21:45 UTC	Landos Biopharma, Inc. LABP · Entity 90644	Disposition to issuerStock Option (right to buy) · Derivative	1,800	Not disclosed Strike: $9.10	Not disclosed	Disclosure SEC source: 0001415889-24-014337 · form4-05232024_050509.xml · derivative · entry 2 Adsett Roger · CIK 0001685904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,800 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. Read SEC document
May 23, 2024 Filed May 23, 2024 21:45 UTC	Landos Biopharma, Inc. LABP · Entity 90644	Disposition to issuerStock Option (right to buy) · Derivative	1,800	Not disclosed Strike: $3.30	Not disclosed	Disclosure SEC source: 0001415889-24-014337 · form4-05232024_050509.xml · derivative · entry 1 Adsett Roger · CIK 0001685904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,800 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes. Read SEC document
May 17, 2024 Filed May 17, 2024 20:15 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	5,945	$25.09	$149,160.05	Disclosure SEC source: 0001628280-24-024060 · wk-form4_1715976900.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,275 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
May 14, 2024 Filed May 15, 2024 20:31 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	7,857	$25.50	$200,353.50	Disclosure SEC source: 0001628280-24-023589 · wk-form4_1715805079.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,220 F3 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of RSUs and to cover related broker fees. F4 · price: This is the weighted average sales price representing 7,857 shares sold at prices ranging from $25.48 to $25.57 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.